In a phase 3 trial, adults with type 2 diabetes who had not previously received insulin were assigned to receive once-weekly efsitora or once-daily degludec. Efsitora was noninferior to degludec in reducing glycated hemoglobin levels.
The New England Journal of Medicine: Search Results in Gastroenterology
